Medyria

High-Level Overview

Medyria is a Swiss medtech company founded in 2012 (or 2013 per some sources) that develops blood flow velocity (BFV) sensing technology for interventional cardiology.[1][2][4] It offers its sensor as an OEM component for integration into other devices and has created PyCath, a standalone microcatheter that measures both pressure and BFV simultaneously to assess coronary physiology, including obstructive and microvascular ischemia in conditions like angina pectoris and coronary artery disease (CAD).[1][3][4][5] Serving cardiologists and healthcare institutions, Medyria addresses unmet needs in real-time coronary and microvascular assessment during catheter-based procedures, reducing procedural risks, time, and costs while improving patient outcomes.[2][5] At Series B-II stage with $10.37M raised (latest $3.98M two years ago), the company shows growth via recent milestones like the March 2025 KENOBI Trial launch and preclinical completion for PyCath.[1][5]

Origin Story

Medyria emerged from market research identifying gaps in real-time coronary and microvascular assessment, leading to its unique BFV sensing technology protected by four patent families in Europe, China, Japan, and the US.[2] Founded in Winterthur, Switzerland, by Dr. Mauro Sette (a biomedical and cardiac engineering expert), the company started in 2012-2013 with a lean team of about six combining over 50 years in engineering, clinical research, and business development.[1][2][5] Early traction included OEM sensor sales and development of devices like PhysioCath (an all-in-one angiography tool), followed by PyCath as the flagship for full heart physiology evaluation.[2][4][5] Pivotal moments: securing CHF 1.5M and CHF 3.7M funding rounds, completing preclinical PyCath work, a first-in-human trial with 40 patients in Germany, and OEM agreements.[5]

Core Differentiators

• Unique BFV Sensing Technology: Direct, real-time measurement of blood flow velocity in coronary arteries and microvasculature, enabling comprehensive physiology assessment beyond standard pressure metrics—only PyCath offers simultaneous pressure and BFV in a single microcatheter.[1][3][4][5]
• Plug-and-Play Devices: PyCath and PhysioCath integrate seamlessly into standard angiography, minimizing procedural manipulations, complications, and costs while boosting safety and efficiency for cardiologists.[2][5]
• Strong IP and OEM Model: Four patent families secure core tech; OEM sales enable partnerships for new cardiovascular devices, diversifying revenue beyond standalone products.[2][4]
• Clinical Momentum: Preclinical completion, first-in-human trial success, and the 2025 KENOBI pilot for obstructive/microvascular ischemia validation position it for regulatory approval.[1][5]

Role in the Broader Tech Landscape

Medyria rides the wave of precision cardiology amid rising CAD and angina prevalence, where traditional angiography misses microvascular issues affecting ~50% of patients—its BFV tech expands eligibility to 100% by completing microvascular assessment.[5] Timing aligns with post-pandemic demand for efficient, minimally invasive procedures and regulatory pushes for advanced diagnostics (e.g., FDA Fast Track analogs in medtech).[1] Favorable market forces include aging populations, medtech funding resurgence in Europe/Switzerland's innovation hubs like Technopark Winterthur, and OEM demand for sensor tech in cardiovascular devices.[2][5] It influences the ecosystem by enabling partners to build BFV-enabled tools, potentially standardizing real-time flow metrics in cath labs and accelerating adoption of integrated ischemia diagnostics.[1][3]

Quick Take & Future Outlook

Medyria's PyCath positions it for clinical adoption and market entry post-KENOBI Trial results, with topline data potentially by late 2025 driving regulatory milestones and partnerships.[1][5] Trends like AI-enhanced cath lab tools and microvascular-focused therapies will amplify its edge, while global expansion (e.g., via Portuguese branch) and further funding could scale OEM/standalone sales.[4][5] Its influence may grow by redefining cardiology workflows, tying back to its core strength: transforming incomplete coronary studies into full physiological insights for better patient care.[1][2]